Keri Toner

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Hodgkin Lymphoma

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Birte Wistinghausen, Keri Toner, Donald A Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela A Chansky, Gloria Pezzella, Lauren Saguilig, Robert J Hayashi, Harshal A Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick J Hanley, Michelle L Hermiston, Carl E Allen, Catherine M Bollard
ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children's Oncology Group Study. Blood advances (2024)
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela A Chansky, Gloria Pezzella, Lauren Saguilig, Robert J Hayashi, Harshal A Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick J Hanley, Michelle L Hermiston, Carl E Allen, Catherine M Bollard
ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children's Oncology Group Study. Blood advances (2024)
Jonathan D Bender, Sudarshawn Damodharan, Christian M Capitini, Amy Moskop, Keri Toner, Anant Vatsayan, Julie-An Talano, Christina Baggott, Deborah E Schiff, Emmanuel Katsanis, Arunkumar J Modi, Troy C Quigg, Sunil S Raikar, Liora M Schultz, Lauren Pommert
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood advances 8 (15) (2024)
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela A Chansky, Gloria Pezzella, Lauren Saguilig, Robert J Hayashi, Harshal Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick Hanley, Michelle L Hermiston, Carl E Allen, Catherine M Bollard
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood advances 8 (5) (2024)
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela A Chansky, Gloria Pezzella, Lauren Saguilig, Robert J Hayashi, Harshal Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick Hanley, Michelle L Hermiston, Carl E Allen, Catherine M Bollard
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood advances 8 (5) (2024)
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela A Chansky, Gloria Pezzella, Lauren Saguilig, Robert J Hayashi, Harshal Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick Hanley, Michelle L Hermiston, Carl E Allen, Catherine M Bollard
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood advances 8 (5) (2024)
Jonathan D Bender, Sudarshawn Damodharan, Christian M Capitini, Amy Moskop, Keri Toner, Anant Vatsayan, Julie-An Talano, Christina Baggott, Deborah E Schiff, Emmanuel Katsanis, Arunkumar J Modi, Troy C Quigg, Sunil S Raikar, Liora M Schultz, Lauren Pommert
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood advances 8 (15) (2024)
Jonathan D Bender, Sudarshawn Damodharan, Christian M Capitini, Amy Moskop, Keri Toner, Anant Vatsayan, Julie-An Talano, Christina Baggott, Deborah E Schiff, Emmanuel Katsanis, Arunkumar J Modi, Troy C Quigg, Sunil S Raikar, Liora M Schultz, Lauren Pommert
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood advances (2024)
Keri Toner, Carl E Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom, Jonathan W Friedberg, Nita L Seibel, Kara Kelly
Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma. EJHaem 4 (4) (2023)
Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie L Grant, Maja Stanojevic, Christopher Andrew Lazarski, Abeer Shibli, Stephanie Ann Bien, Philp Maglo, Fahmida Hoq, Reuven J Schore, Martha J Glenn, Boyu Hu, Patrick J Hanley, Richard F Ambinder, Catherine M Bollard
Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma. Blood advances (2021)
Keri Toner, Catherine M Bollard
EBV+ Lymphoproliferative Diseases: Opportunities for leveraging EBV as a Therapeutic Target. Blood (2021)